RPS29A Antibody

What is RPS29 and what cellular functions does it perform?

RPS29 (ribosomal protein S29) is a component of the small ribosomal subunit with significant roles in protein synthesis. In humans, this protein consists of 56 amino acid residues and has a molecular mass of approximately 6.7 kDa. It is predominantly localized in the endoplasmic reticulum and cytoplasm, with wide expression across multiple tissue types. As a member of the Universal ribosomal protein uS14 family, RPS29 contributes to the structural integrity and functionality of the ribosome, which is essential for cellular protein synthesis processes. The ribosome functions as a large ribonucleoprotein complex responsible for translating mRNA into proteins within the cell . Mutations in the RPS29 gene are associated with Diamond-Blackfan anemia, highlighting its clinical significance beyond basic cellular function.

What is the difference between RPS29 and RPS29A designations?

The designation difference primarily relates to nomenclature systems across species. In humans, the protein is commonly referred to as RPS29, while in some model organisms like yeast, the designation RPS29A may be used to distinguish between paralogs. The core protein functions remain similar across species, with RPS29 being the predominant term used in human research contexts. When working with antibodies, it's important to verify which specific protein isoform they target, as up to two different isoforms have been reported for human RPS29 . This distinction becomes particularly important when conducting comparative studies across different model organisms, as orthologous proteins may have slight variations in sequence and epitope presentation.

What are the common applications for RPS29 antibodies in research?

RPS29 antibodies are versatile research tools employed across multiple experimental techniques. The most common applications include:

These applications enable researchers to investigate RPS29 expression patterns, subcellular localization, protein-protein interactions, and potential roles in disease states . For optimal results, application-specific optimization is recommended, as performance can vary between antibody clones and experimental conditions.

What criteria should guide the selection of an appropriate RPS29 antibody?

When selecting an RPS29 antibody, researchers should consider multiple factors to ensure experimental success:

• Application compatibility: Verify that the antibody has been validated for your specific application (WB, IHC, ICC, etc.).

• Species reactivity: Confirm reactivity with your experimental model organism. Commercial RPS29 antibodies show varying reactivity patterns with human, mouse, rat, and other species .

• Antibody type: Consider whether monoclonal (higher specificity) or polyclonal (broader epitope recognition) better suits your experimental needs.

• Conjugation status: Determine if you need an unconjugated antibody or one conjugated to a reporter (HRP, FITC, biotin).

• Epitope location: For specific isoform detection, verify the epitope region (N-terminal, C-terminal, or internal).

• Validation evidence: Review available validation data, including published citations and manufacturer validation images.

• Clone information: For monoclonal antibodies, note the clone designation (e.g., 3G9) as this indicates the specific hybridoma line .

Creating a decision matrix with these criteria can facilitate systematic antibody selection aligned with your specific research objectives.

How should RPS29 antibody specificity be validated?

Rigorous validation is essential to ensure experimental reliability. Recommended validation approaches include:

• Positive and negative tissue controls: Test antibodies on tissues with known RPS29 expression patterns. Human pancreas tissue has been used successfully for validating RPS29 antibodies in IHC applications .

• Knockdown/knockout verification: Compare antibody signal between wild-type samples and those with RPS29 knocked down or knocked out.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide to confirm specific blocking of the signal.

• Multiple antibody comparison: Test different antibodies targeting distinct epitopes of RPS29 to confirm consistent localization patterns.

• Molecular weight verification: Confirm that the detected band in Western blot corresponds to the expected size (~6.7 kDa for RPS29).

• Cross-reactivity assessment: Test on samples from multiple species to confirm predicted reactivity patterns.

• Recombinant protein controls: Use purified recombinant RPS29 as a positive control for quantitative assays.

Documenting these validation steps enhances experimental credibility and facilitates troubleshooting if unexpected results occur.

What is the optimal protocol for Western blot detection of RPS29?

Given the small size of RPS29 (6.7 kDa), specific considerations are needed for successful Western blot detection:

• Sample preparation:

  • Use RIPA or NP-40 buffer with protease inhibitors

  • Include phosphatase inhibitors if phosphorylation status is relevant

  • Perform sample reduction with DTT or β-mercaptoethanol

• Gel electrophoresis:

  • Use high percentage (15-20%) polyacrylamide gels or gradient gels (4-20%)

  • Consider tricine-SDS-PAGE systems optimized for small proteins

  • Load appropriate positive controls (e.g., lysates from tissues with high RPS29 expression)

• Transfer conditions:

  • Use PVDF membrane with 0.2 μm pore size (rather than 0.45 μm)

  • Transfer at lower voltage (30V) for longer time (2 hours) or use semi-dry transfer

  • Consider adding SDS (0.1%) to transfer buffer to improve small protein transfer

• Blocking and antibody incubation:

  • Block with 5% non-fat milk or BSA in TBST

  • Dilute primary antibody according to manufacturer recommendations (typically 1:1000 for RPS29)

  • Incubate overnight at 4°C with gentle agitation

  • Use HRP-conjugated secondary antibody at 1:5000-1:10000

• Detection:

  • Use enhanced chemiluminescence substrates optimized for low-abundance proteins

  • Consider longer exposure times due to potentially lower signal intensity

After detection, verification of the band at approximately 6.7 kDa is essential for confirming specificity . For quantitative analysis, normalization to housekeeping genes like GAPDH or β-actin should be performed, though caution is needed as these standard loading controls have significantly higher molecular weights than RPS29.

How should RPS29 antibodies be used for immunohistochemistry and immunocytochemistry?

Successful IHC and ICC applications require attention to fixation, antigen retrieval, and specific staining protocols:

• Tissue/cell preparation:

  • For IHC: Use formalin-fixed, paraffin-embedded (FFPE) or frozen sections

  • For ICC: PFA fixation (4%) with Triton X-100 permeabilization has been successful

  • Consider testing multiple fixation methods if initial results are suboptimal

• Antigen retrieval:

  • For FFPE sections: Heat-induced epitope retrieval in citrate buffer (pH 6.0)

  • Optimize retrieval time (typically 15-20 minutes)

  • Allow slides to cool slowly to room temperature

• Blocking and antibody incubation:

  • Block with 5-10% normal serum from the species of secondary antibody

  • Add 0.1-0.3% Triton X-100 for improved penetration

  • Use optimized primary antibody dilution (1:100-1:1000 range for RPS29)

  • Incubate at 4°C overnight in a humidified chamber

• Detection system:

  • For chromogenic detection: HRP/DAB system with hematoxylin counterstain

  • For fluorescence: Use appropriate fluorophore-conjugated secondaries

  • Include DAPI for nuclear counterstaining in fluorescent applications

• Controls:

  • Include isotype control to assess non-specific binding

  • Use known positive tissue (e.g., human pancreas has been validated)

  • Include no-primary-antibody control

Published validation data demonstrates successful staining of human pancreas tissue at 1:1000 dilution for IHC-P and human A-431 cells at 4μg/ml for ICC/IF . Expected staining pattern should align with the known subcellular localization of RPS29 in the ER and cytoplasm.

What controls are essential when working with RPS29 antibodies?

Implementing appropriate controls is critical for ensuring experimental validity:

• Positive controls:

  • Tissue/cell types with known high RPS29 expression

  • Recombinant RPS29 protein

  • Overexpression systems (transfected cells)

• Negative controls:

  • Primary antibody omission

  • Isotype control antibody

  • RPS29 knockdown/knockout samples

  • Peptide competition/neutralization

• Technical controls:

  • Loading controls for Western blot (though challenging due to size differences)

  • Housekeeping gene staining for IHC/ICC (e.g., β-actin)

  • Internal tissue controls for IHC (normal adjacent tissue)

• Validation controls:

  • Multiple antibodies targeting different epitopes

  • Different detection methods for the same sample

  • Serial dilution tests to confirm specificity

• Cross-reactivity controls:

  • Testing on non-target species if antibody claims broad reactivity

  • Testing on related proteins if specificity concerns exist

Documenting all controls systematically increases confidence in experimental outcomes and facilitates troubleshooting when unexpected results occur.

How can RPS29 antibodies be utilized to study Diamond-Blackfan anemia?

Diamond-Blackfan anemia (DBA) is a rare congenital disorder characterized by red blood cell aplasia, and mutations in the RPS29 gene (referred to as DBA13) have been identified as one causative factor . RPS29 antibodies can be instrumental in studying this condition through several approaches:

• Expression analysis:

  • Comparing RPS29 protein levels in patient-derived samples versus healthy controls

  • Assessing expression in different hematopoietic lineages

  • Monitoring temporal expression during erythropoiesis

• Functional studies:

  • Co-immunoprecipitation to identify altered protein interactions in mutant RPS29

  • Identifying changes in subcellular localization of mutant versus wild-type protein

  • Evaluating ribosome assembly defects through sucrose gradient analysis

• Diagnostic development:

  • Creating assays to detect abnormal RPS29 expression or localization

  • Developing screening methods for potential DBA cases

• Therapeutic monitoring:

  • Assessing restoration of normal RPS29 levels following experimental treatments

  • Monitoring ribosome function recovery in response to interventions

• Model system validation:

  • Confirming appropriate RPS29 expression in animal or cellular models of DBA

  • Verifying knockdown/knockout efficiency in experimental systems

These applications require highly specific antibodies with validated performance in the relevant experimental systems. When studying patient-derived samples, antibodies that can distinguish between wild-type and mutant forms may be particularly valuable for understanding pathophysiological mechanisms.

What considerations apply when using RPS29 antibodies across different model organisms?

• Epitope conservation:

  • Verify sequence homology in the epitope region between target species

  • Consider using antibodies raised against conserved epitopes for cross-species studies

  • Validate antibody reactivity in each species experimentally before proceeding

• Isoform differences:

  • Account for species-specific isoforms that may alter epitope presentation

  • Be aware that some species may have paralogs (e.g., RPS29A/B) requiring specific detection

• Background considerations:

  • Optimize blocking conditions for each species to minimize non-specific binding

  • Consider species-specific secondary antibodies to reduce background

• Application modifications:

  • Adjust antibody concentrations based on target abundance in different species

  • Modify fixation protocols based on tissue-specific requirements

  • Adapt antigen retrieval methods for species-specific tissues

• Validation requirements:

  • Perform Western blots to confirm correct molecular weight in each species

  • Include positive controls from the specific species being studied

  • Consider sequence alignment analysis to predict potential cross-reactivity

Many commercial RPS29 antibodies list reactivity with multiple species, but experimental validation remains essential before conducting cross-species comparative studies .

What are common challenges when working with RPS29 antibodies and how can they be addressed?

Several technical challenges may arise when working with RPS29 antibodies, each requiring specific troubleshooting approaches:

• Low signal intensity in Western blot:

  • Cause: Small protein size (6.7 kDa) leading to poor transfer or rapid passage through gel

  • Solution: Use higher percentage gels (15-20%), optimize transfer for small proteins, increase antibody concentration, or use more sensitive detection methods

• Multiple bands in Western blot:

  • Cause: Cross-reactivity, post-translational modifications, or isoforms

  • Solution: Validate with knockout/knockdown controls, use more specific antibodies, or optimize blocking conditions

• High background in IHC/ICC:

  • Cause: Non-specific binding or inadequate blocking

  • Solution: Increase blocking time/concentration, optimize antibody dilution, or use alternative blocking agents

• Variable results between experiments:

  • Cause: Antibody degradation, sample variability, or protocol inconsistencies

  • Solution: Aliquot antibodies to avoid freeze-thaw cycles, standardize sample preparation, and maintain detailed protocol records

• Poor reproducibility across applications:

  • Cause: Antibody may be application-specific

  • Solution: Verify antibody validation for specific applications, consider using different antibodies optimized for each application

• Discrepancies between antibody sources:

  • Cause: Different epitope targets or production methods

  • Solution: Compare validation data, test multiple antibodies side-by-side, or select based on specific experimental needs

• Difficulties detecting endogenous RPS29:

  • Cause: Low expression levels in certain cell types

  • Solution: Enrich for ribosomal fractions, use more sensitive detection methods, or increase exposure times

A systematic approach to troubleshooting, combined with appropriate controls and thorough documentation, can help resolve most technical issues encountered with RPS29 antibodies.

How does fixation methodology affect RPS29 antibody performance in immunohistochemistry?

Fixation can significantly impact antibody accessibility to RPS29 epitopes, affecting staining quality and localization accuracy:

• Formalin fixation effects:

  • Cross-linking may mask RPS29 epitopes, particularly affecting small proteins

  • Extended fixation times can exacerbate epitope masking

  • Antigen retrieval becomes critical for successful staining

  • Successfully used with RPS29 antibodies at 1:1000 dilution on human pancreas tissue

• Alternative fixation approaches:

  • PFA fixation with Triton X-100 permeabilization works well for cultured cells (e.g., A-431 cell line)

  • Methanol fixation may preserve some epitopes better than aldehyde-based methods

  • Acetone fixation can be suitable for frozen sections

  • Heat-mediated fixation may preserve certain conformational epitopes

• Optimization strategies:

  • Test multiple fixation methods in parallel

  • Adjust fixation duration based on tissue thickness

  • Consider dual fixation protocols for difficult samples

  • Modify antigen retrieval based on fixation method

• Technical recommendations:

  • For FFPE tissues: Limit fixation to 24 hours when possible

  • For frozen sections: Brief fixation (10 minutes) often sufficient

  • For cell cultures: 10-20 minutes in 4% PFA typically optimal

  • Always include fixation details in methodology reporting

The optimal fixation method may vary depending on the specific RPS29 antibody clone, tissue type, and downstream application. Published data demonstrates successful staining using both FFPE tissues with antigen retrieval and PFA-fixed cultured cells .

How can RPS29 antibodies contribute to ribosome biogenesis research?

RPS29 antibodies offer valuable tools for investigating ribosome assembly and function:

• Ribosome assembly dynamics:

  • Track RPS29 incorporation into pre-ribosomal particles

  • Monitor temporal aspects of small subunit formation

  • Investigate co-localization with other ribosomal proteins and assembly factors

• Stress response studies:

  • Assess changes in RPS29 localization during cellular stress

  • Monitor ribosome composition alterations under various conditions

  • Evaluate extra-ribosomal functions that may emerge during stress

• Developmental biology applications:

  • Track tissue-specific ribosome composition during development

  • Investigate specialized ribosomes in different cell types

  • Monitor RPS29 expression during cellular differentiation

• Disease mechanism investigations:

  • Beyond DBA, examine RPS29 involvement in other ribosomopathies

  • Investigate potential roles in cancer progression

  • Explore connections to neurodegenerative disorders

• Technical applications:

  • Use as markers for ribosome purification validation

  • Employ in proximity ligation assays to study ribosome-associated protein interactions

  • Utilize in ribosome profiling quality control

These applications leverage the specificity of RPS29 antibodies to provide insights into fundamental cellular processes and disease mechanisms related to ribosomal function.

What are the considerations for quantitative analysis of RPS29 expression?

Accurate quantification of RPS29 requires attention to several methodological factors:

• Western blot quantification:

  • Challenge: Small size makes standard loading controls inappropriate

  • Solution: Use other small ribosomal proteins as controls or total protein normalization methods

  • Consider spike-in controls for absolute quantification

• IHC/ICC quantification:

  • Options: H-score, digital image analysis, or staining intensity categorization

  • Standardize acquisition parameters across samples

  • Use automated analysis software to reduce subjective interpretation

• ELISA-based quantification:

  • Develop standard curves using recombinant RPS29

  • Include spike-in controls to assess recovery efficiency

  • Account for potential matrix effects in complex samples

• Flow cytometry considerations:

  • Requires careful permeabilization to access intracellular RPS29

  • May need signal amplification due to relatively low abundance

  • Use appropriate isotype controls for accurate gating

• Normalizing factors:

  • Consider cell number, total protein content, or other ribosomal proteins

  • Be aware of potential compensatory mechanisms affecting other ribosomal proteins

  • Document normalization approach clearly in methodology

• Statistical analysis:

  • Account for technical and biological replicates

  • Consider appropriate statistical tests based on data distribution

  • Report variability measures (standard deviation, standard error, etc.)

Quantitative analysis should always be accompanied by appropriate validation steps and detailed methodology reporting to ensure reproducibility and reliability of findings.